Mineralys Therapeutics, Inc. develops medicines for hypertension and related comorbidities driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for hypertension, chronic kidney disease, obstructive sleep apnea and other aldosterone-related conditions.
Mineralys news commonly covers lorundrostat clinical data, FDA regulatory updates, New Drug Application developments, and corporate updates tied to clinical and regulatory funding. Other recurring announcements include quarterly financial results, health care conference participation, executive appointments, and employee equity inducement awards under Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics (MLYS) will present new lorundrostat data from Launch-HTN at ASN Kidney Week 2026, taking place October 21–25 in Denver. The oral presentation focuses on blood pressure and albuminuria, or albumin in urine, reduction in chronic kidney disease stages 1 to 3. Launch-HTN was a Phase 3 trial in adults whose blood pressure remained uncontrolled despite two to five antihypertensive medications.
Mineralys Therapeutics (Nasdaq: MLYS) announced five abstract presentations at the American Heart Association Hypertension Scientific Sessions, taking place October 7–11, 2026.
The meeting in Arlington, Virginia, includes an October 8 oral presentation on the Explore-OSA trial of lorundrostat in moderate-to-severe obstructive sleep apnea and hypertension. Four posters scheduled for October 9 cover blood pressure responders in Launch-HTN, lorundrostat in a rat model of heart and kidney injury, spironolactone treatment patterns, and a literature review and combined analysis of studies on adherence to mineralocorticoid receptor antagonists.
Mineralys Therapeutics (Nasdaq: MLYS) granted equity inducement awards to two new non-executive employees on September 28, 2026.
The grants cover 46,430 stock option shares and 34,823 restricted stock units under the 2025 Employment Inducement Incentive Award Plan. Both vest over four years, subject to continued service. Options vest 25% on the first anniversary of September 28, 2026, then 1/48th monthly thereafter. Restricted stock units vest 25% on each of the first four anniversaries. The awards were employment inducements under Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics (MLYS) will participate in the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026.
Management's fireside chat is scheduled for 12:00 p.m. ET. A live webcast will be available on the “News & Events” page in the Investor Relations section of the company's website.
Mineralys Therapeutics (MLYS) announced a November 8, 2026 presentation of long-term lorundrostat data at the American Heart Association Scientific Sessions.
The late-breaking presentation will cover efficacy and safety data from the ongoing Transform-HTN open-label extension trial in uncontrolled hypertension. Manish Saxena is scheduled to present at 3:30 p.m. CT. The conference takes place November 6–9 in Chicago.
Mineralys Therapeutics (MLYS) granted equity inducement awards to a new non-executive employee on September 21, 2026, under its 2025 Employment Inducement Incentive Award Plan.
The Compensation Committee approved a stock option covering 14,880 shares of common stock and a restricted stock unit (RSU) award covering 11,160 shares. The option vests over four years, with 25% of the shares vesting on the first anniversary of the September 21, 2026 vesting commencement date, and 1/48th vesting monthly thereafter, subject to continued service. The RSU award vests over four years in four equal annual installments starting on the first anniversary of the same commencement date, subject to continued service. The awards were made as inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics (MLYS) granted inducement equity awards to two new non-executive employees effective September 8, 2026, under its 2025 Employment Inducement Incentive Award Plan.
The grants include stock options covering an aggregate of 29,760 shares and restricted stock units (RSUs) covering an aggregate of 22,320 shares of common stock. The options vest over four years, with 25% vesting on the first anniversary of the September 8, 2026 vesting commencement date and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued service. The RSUs vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the same vesting commencement date, subject to continued service and in accordance with Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics (Nasdaq: MLYS) announced that its management will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, held September 8-10, 2026. The company is scheduled for a fireside chat on Wednesday, September 9, 2026 at 4:30 p.m. EDT, with a live webcast available via its Investor Relations website.
Mineralys Therapeutics (Nasdaq: MLYS) reported that on August 10, 2026, a majority of its independent directors granted inducement equity awards to newly appointed Chief Medical Officer Dr. Terry Ferguson under the 2025 Employment Inducement Incentive Award Plan.
The grant includes a stock option for 135,000 shares of common stock and a restricted stock unit (RSU) award for 102,400 shares. The option vests over four years, with 25% vesting on the first anniversary of the vesting commencement date, August 10, 2026, and the remainder vesting in equal monthly installments over the following three years, subject to continued service. The RSUs vest in four equal annual installments over four years starting August 10, 2026, also subject to continued service. According to Mineralys, these awards were granted as an inducement material to Dr. Ferguson’s employment, in line with Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics (Nasdaq: MLYS) reported second quarter 2026 results and progress on lorundrostat, its aldosterone synthase inhibitor for hypertension. The FDA is reviewing the lorundrostat NDA with a PDUFA target date of December 22, 2026, and the company is advancing commercial launch preparations.
Mineralys appointed cardiovascular specialist James J. “Terry” Ferguson III, M.D. as Chief Medical Officer, effective August 10, 2026, while former CMO David Rodman becomes a full-time Strategic Advisor. The company strengthened lorundrostat economics by amending its Tanabe license, eliminating royalties in exchange for a $200 million upfront payment and up to $255 million in commercial milestones plus up to $10 million tied to a potential second indication.
Second quarter 2026 cash, cash equivalents and investments totaled $661.4 million, and Mineralys believes this will fund planned operations, including a potential launch, into 2028. Quarterly R&D expenses rose to $221.4 million, largely due to the Tanabe payment, G&A expenses were $24.7 million, and net loss was $241.1 million or $(2.85) per share.